BioCatalyst

Pembrolizumab, Conventional Radiotherapy (Bladder only), Conventional Radiotherapy (Bladder and pelvic nodes), Hypofractionated Radiotherapy (Bladder only) — catalyst calendar

1 verified catalyst event(s) referencing Pembrolizumab, Conventional Radiotherapy (Bladder only), Conventional Radiotherapy (Bladder and pelvic nodes), Hypofractionated Radiotherapy (Bladder only), each linked to its official source. Verified as of 2026-10-02.

Upcoming

DateEventCompanyDrugOfficial source & verification
2027-01-31
in 4mo
ESTIMATED
 READOUT
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiothe
Phase 3 · Urinary Bladder Neoplasms
 Merck Sharp & Dohme LLC Pembrolizumab, Conventional Radiotherapy ClinicalTrials.gov ↗
✓ Source-checked 2026-10-02
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.